TP53 and ovarian serous carcinoma: Consistent with this view, TP53 mutation was identified as a dominant driver mutation in OCS (54.5%), with the highest mutation frequency, while still significantly lower than that in UCS (62%–91%) and serous ovarian carcinoma (36, 37).